US appeals court affirms Actonel patent, blocking Teva's generic
This article was originally published in Scrip
Executive Summary
The US Court of Appeals for the Federal Circuit has ruled in favour of Procter & Gamble in a patent infringement battle with Teva Pharmaceutical Industries, and affirmed a lower court ruling that said that P&G's compound patent for its osteoporosis drug Actonel (risedronate) is valid.